stonks4u
Sign up free
TSHA logo

TSHA Taysha Gene Therapies, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$5.95
-0.04 (-0.67%)

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development …

Market Cap: $1.90Bwww.tayshagtx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 11Aug 11

Quote

Day Range
$5.72 – $6.01
52-Week Range
$2.71 – $7.30
Volume
$2.13M
Market Cap
$1.90B
50-Day Avg
$6.07
200-Day Avg
$5.32
Prev Close
$5.99
Open
$5.90

Valuation & Ratios

P/E Ratio
-16.18
EPS
$-0.34
P/B Ratio
7.12
P/S Ratio
179.93
Debt/Equity
0.07
Current Ratio
12.23
Dividend Yield
+0.0%
Gross Margin
+100.0%

Returns & Efficiency

Return on Equity
-44.1%
Return on Assets
-31.7%
FCF Yield
-5.3%
EV/EBITDA
-13.52

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$9.77M$-109.00M$-0.34
2024$8.33M$-89.30M$-0.36
2023$15.45M$-111.57M$-0.96
2022$2.50M$-166.01M$-3.78
2021$0.00$-174.52M$-4.64

Social Signal Score

51
5d
51
3 mentions
—
30d
51
3 mentions
—
60d
51
3 mentions
—
90d
51
3 mentions
—
news: 3

Earnings

Tue, Nov 3(in 3 months)

Consensus estimate $-0.14 per share

4of 7 quarters beat consensus

Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Tue, Aug 11$-0.13 vs $-0.11miss
  • Wed, May 6$-0.12 vs $-0.10miss
  • Thu, Mar 19$-0.08 vs $-0.11beat
  • Tue, Nov 4$-0.09 vs $-0.09beat
  • Tue, Aug 12$-0.09 vs $-0.07miss
  • Thu, May 15$-0.08 vs $-0.08beat

Estimates and results for TSHA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

TSHAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsseekingalpha.com·3d ago·Positive

    Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsmarketbeat.com·3d ago·Negative

    Taysha Gene Therapies Q2 Earnings Call Highlights Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.

    View source ↗
  • Newsglobenewswire.com·3d ago·Neutral

    Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

    View source ↗